A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma

What is the purpose of this trial?

The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to patients with metastatic colorectal carcinoma. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of MGD007 will also be assessed.

MacroGenics, Inc.

Dates: 11/29/2017 - 01/31/2018

Last Updated: 11/30/2017

Study HIC#: 2000021520

Get Involved

For more information about this study, contact:
Kamil Sadowski
+1 203-785-6666

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Stacey M Stein

Principal Investigator